Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation
  • Glutamic acid
    pills inwards 
    MARBIOFARM, OJSC     Russia
  • Glutamic acid
    pills inwards 
  • АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    A.16.A.A   Amino acids and their derivatives

    Pharmacodynamics:

    A replaceable amino acid, like a neurotransmitter, stimulates processes of transmission of excitation in the central nervous system. It is part of the substrate of myofibrils, due to which it participates in the processes of muscle tissue reduction. Participates in the synthesis of adenosine triphosphoric acid and acetylcholine, promotes the transport of potassium ions into the cell. Disinfects ammonia and takes part in its excretion from the body.

    Has a hepatoprotective, detoxification action. Oppresses the secretion of parietal cells of the stomach.

    Pharmacokinetics:After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract.

    Penetrates through the blood-brain and placental barrier, accumulates in the white substance of the brain. Metabolism in the liver.

    Elimination by the kidneys - about 7% unchanged.

    Indications:It is used in the complex treatment for epilepsy, schizophrenia, reactive depressive states, psychoses, poliomyelitis, Down's disease. Used in children's cerebral palsy and the consequences of birth trauma.It is used as an antidote for toxic neuropathy, which developed due to the use of isonicotinic acid hydrazides.

    I.A80-A89.A80   Acute poliomyelitis

    V.F20-F29.F20   Schizophrenia

    V.F20-F29.F21   Chrysotile disorder

    V.F20-F29.F22   Chronic delusional disorders

    V.F20-F29.F29   Inorganic psychosis, unspecified

    V.F20-F29.F25   Schizoaffective disorder

    V.F30-F39.F31   Bipolar affective disorder

    V.F30-F39.F32   Depressive episode

    V.F30-F39.F33   Recurrent depressive disorder

    V.F40-F48.F41.2   Mixed anxiety and depressive disorder

    V.F50-F59.F51.2   Sleep and wakefulness disorder inorganic etiology

    V.F70-F79.F79   Mental retardation, unspecified

    VI.G40-G47.G40   Epilepsy

    VI.G60-G64.G63 *   Polyneuropathy in diseases classified elsewhere

    VI.G80-G83.G80   Cerebral palsy

    IX.I60-I69.I69   Effects of cerebrovascular disease

    Contraindications:Increased excitability, renal insufficiency, anemia, leukopenia, peptic ulcer and duodenal ulcers, obesity, febrile conditions, individual intolerance, children under 3 months.

    Carefully:Hepatic insufficiency, hypersensitivity.

    Pregnancy and lactation:Recommendations for FDA - Category B. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Use in children

    Up to 5 years: inside 30 minutes before meals as a suspension 3 times a day

    up to 1 year - 10 ml (100 mg);

    1-2 years - 15 ml (150 mg);

    3-5 years - 25 ml each (250 mg).

    From the age of 5: inside 3 times a day

    5-6 years - 400 mg each;

    7-9 years - 500 mg each;

    From 10 years - to 1 g.

    Adults

    Inside 30 minutes before meals, 1 g 2-3 times a day.

    The highest daily dose: 3 g.

    The highest single dose: 1 g.

    Side effects:

    Central and peripheral nervous system: increased excitability, insomnia.

    Digestive system: nausea, vomiting, diarrhea.

    Allergic reactions.

    Overdose:Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:Clinically significant interactions are not described.

    Special instructions:

    After ingestion in the form of a suspension or powder, rinse the mouth with a weak solution of sodium hydrogencarbonate.

    With dyspepsia, glutamic acid is recommended during or immediately after meals.

    Instructions
    Up